NCT00810485

ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)

A Phase 2B, Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-ranging, Multi-centre Study to Investigate the Efficacy, Safety and Tolerability of the mGluR5 Negative Allosteric Modulator ADX10059 in Patients With Gastroesophageal Reflux Disease (GERD) Who Are Partial Responders to Proton Pump Inhibitor (PPI) Treatment

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 298 (actual)
• Sponsor: Addex Pharma S.A. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the effect of ADX10059 in patients with gastroesophageal reflux disease who are partial responders to proton pump inhibitors

Conditions

• Gastroesophageal Reflux

Interventions

Type	Name	Description
DRUG	ADX10059	oral administration
DRUG	ADX10059	oral administration
DRUG	ADX10059	oral administration
DRUG	ADX10059 Matching Placebo	oral administration

Timeline

• Start date: 2008-12-01
• Primary completion: 2009-12-01
• First posted: 2008-12-18
• Last updated: 2012-07-16

Locations

40 sites across 5 countries: United States, France, Germany, Netherlands, Switzerland